ReviewCancer medicine2016
CXCL9: evidence and contradictions for its role in tumor progression.
Review in Cancer medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 105 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
105 citing papers in PubMed, 1 synthesis or guideline pooled it, 169 citations in OpenAlex.
- The genomic architecture of circulating cytokine levels points to drug targets for immune-related diseases.Communications biology · 2025Pooled it
- Pan-cancer analysis of longitudinal metastatic tumors reveals genomic alterations and immune landscape dynamics associated with pembrolizumab sensitivity.Nature communications · 2021Trial
- The influence of dexmedetomidine and propofol on circulating cytokine levels in healthy subjects.BMC anesthesiology · 2019Trial
- Unveiling Endotypes in Systemic Lupus Erythematosus Through Multiomic Analysis: Insights Into Cardiovascular and Renal Complications.Arthritis & rheumatology (Hoboken, N.J.) · 2026Article
- A novel diagnostic serum protein signature for pediatric inflammatory bowel disease.Journal of pediatric gastroenterology and nutrition · 2026Observational
- High-Throughput Proteomic Profiling to Evaluate Differentiation Syndrome With Menin Inhibition.Molecular & cellular proteomics : MCP · 2026Article
- Tissue IL-6/LIF/LIFR and CXCL9 Expression Correlates with High-Risk NBI Patterns and Squamous Cell Carcinoma in Vocal Fold Lesions.International journal of molecular sciences · 2026Article
- CXCL9 associates with experimental neuromyelitis optica spectrum disorder following adoptive transfer of Tfh and Th17 cells.Frontiers in immunology · 2026Article
- Inactivation of interleukin-15 reduces spontaneous atherosclerosis inFrontiers in physiology · 2026Article
- Targeting cellular source-specific CXCL9 signaling for immunotherapy in oral squamous cell carcinoma.Frontiers in immunology · 2026Review
- Xiaoyao San alleviates emotional distress - induced TNBC growth through augmenting intratumoral CD8Frontiers in immunology · 2026Article
- TAPINTO: A Novel Algorithm for Tumor-Associated Antigen Prediction Based on Information about Target Overexpression.Computational and structural biotechnology journal · 2026Article
- Metabolomics reveal distinct molecular pathways associated with future risk of Crohn's Disease.Gut microbes · 2025Article
- STAT3 Inhibition to Treat Ulcerative Colitis-Associated Colorectal Cancer.International journal of molecular sciences · 2025Article
- In situ extended immune activation instantly after tumor resection by oncolytic virus controls postoperative tumor recurrence.Cell reports. Medicine · 2025Article
- Transcriptome analysis of HPV16-positive cells expressing intrabodies targeting E6 and E7 oncoproteins to unravel intrabody antitumor activity.Journal of translational medicine · 2025Article
- Bioinformatics Analysis of Tumor-Associated Macrophages in Hepatocellular Carcinoma and Establishment of a Survival Model Based on Transformer.International journal of molecular sciences · 2025Article
- Piceatannol Attenuates Benzo[Journal of agricultural and food chemistry · 2025Article
- Interferon Epsilon Loss Is Elusive 9p21 Link to Immune-Cold Tumors, Resistant to Immune Checkpoint Therapy, and Endogenous CXCL9/10 Induction.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2025Review
- The current findings on the gut-liver axis and the molecular basis of NAFLD/NASH associated with gut microbiome dysbiosis.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
45 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chemokines are a group of low molecular weight peptides. Their major function is the recruitment of leukocytes to inflammation sites, but they also play a key role in tumor growth, angiogenesis, and metastasis. In the last few years, accumulated experimental evidence supports that monokine induced by interferon (IFN)-gamma (CXCL9), a member of CXC chemokine family and known to attract CXCR3- (CXCR3-A and CXCR3-B) T lymphocytes, is involved in the pathogenesis of a variety of physiologic diseases during their initiation and their maintenance. This review for the first time presents the most comprehensive summary for the role of CXCL9 in different types of tumors, and demonstrates its contradictory role of CXCL9 in tumor progression. Altogether, this is a useful resource for researchers investigating therapeutic opportunities for cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.